Reperfusion injury in humans: a review of clinical trials on reperfusion injury inhibitory strategies - PubMed (original) (raw)
Review
Reperfusion injury in humans: a review of clinical trials on reperfusion injury inhibitory strategies
Maurits T Dirksen et al. Cardiovasc Res. 2007.
Abstract
The principal therapy in patients with myocardial infarction to limit infarct size is myocardial reperfusion by mechanical or pharmacological intervention. Reperfusion has been proposed to cause myocardial injury beyond that caused by the preceding ischaemia, termed "reperfusion injury" (RI). While the precise mechanism of RI is still incompletely understood, a large number of clinical studies have been performed over the past decade targeting some of the postulated mechanisms of RI. These clinical studies were based on experimental data demonstrating significant myocardial salvage. Nevertheless, clinical benefits were absent or very limited. The purpose of this review is to provide an overview of the various strategies that inhibit RI and to discuss potential mechanisms that may contribute to the discrepancy between the promising pre-clinical data and the rather disappointing results obtained from prospective clinical trials. There are numerous differences between the experimental models and clinical studies, including the fact that experimental studies typically use abrupt occlusion and reperfusion protocols in animals with previously healthy myocardium that apparently do not predict the therapeutic efficacy of novel cardioprotective agents in a clinical setting with pre-existing progressive coronary disease, intermittent coronary occlusion, and relatively late reperfusion. However, discrepancies also exist between experimental studies. Future experimental studies of reperfusion injury should use models that mimic the clinical situation more closely. Furthermore, future large clinical trials should only be performed in cases where the drug under investigation proved to reduce RI in a series of well-designed (possibly multicenter) experimental studies and in clinical trials with predefined subgroups.
Similar articles
- Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning.
Ferdinandy P, Schulz R, Baxter GF. Ferdinandy P, et al. Pharmacol Rev. 2007 Dec;59(4):418-58. doi: 10.1124/pr.107.06002. Epub 2007 Nov 29. Pharmacol Rev. 2007. PMID: 18048761 Review. - Realizing the clinical potential of ischemic preconditioning and postconditioning.
Yellon DM, Hausenloy DJ. Yellon DM, et al. Nat Clin Pract Cardiovasc Med. 2005 Nov;2(11):568-75. doi: 10.1038/ncpcardio0346. Nat Clin Pract Cardiovasc Med. 2005. PMID: 16258568 Review. - Myocardial protection at a crossroads: the need for translation into clinical therapy.
Bolli R, Becker L, Gross G, Mentzer R Jr, Balshaw D, Lathrop DA; NHLBI Working Group on the Translation of Therapies for Protecting the Heart from Ischemia. Bolli R, et al. Circ Res. 2004 Jul 23;95(2):125-34. doi: 10.1161/01.RES.0000137171.97172.d7. Circ Res. 2004. PMID: 15271864 Review. - [Reperfusion and postconditioning in acute ST segment elevation myocardial infarction. A new paradigm for the treatment of acute myocardial infarction. From bench to bedside?].
Lupi Herrera E, Gaspar J, González Pacheco H, Martínez Sánchez C, Pastelín Hernández G, Luna Ortiz P, Chávez Cosio E. Lupi Herrera E, et al. Arch Cardiol Mex. 2006 Oct-Dec;76 Suppl 4:S76-101. Arch Cardiol Mex. 2006. PMID: 17469337 Review. Spanish. - Preconditioning, postconditioning and their application to clinical cardiology.
Kloner RA, Rezkalla SH. Kloner RA, et al. Cardiovasc Res. 2006 May 1;70(2):297-307. doi: 10.1016/j.cardiores.2006.01.012. Epub 2006 Mar 3. Cardiovasc Res. 2006. PMID: 16516180 Review.
Cited by
- GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice.
Kempf T, Zarbock A, Widera C, Butz S, Stadtmann A, Rossaint J, Bolomini-Vittori M, Korf-Klingebiel M, Napp LC, Hansen B, Kanwischer A, Bavendiek U, Beutel G, Hapke M, Sauer MG, Laudanna C, Hogg N, Vestweber D, Wollert KC. Kempf T, et al. Nat Med. 2011 May;17(5):581-8. doi: 10.1038/nm.2354. Epub 2011 Apr 24. Nat Med. 2011. PMID: 21516086 - NHE inhibition does not improve Na(+) or Ca(2+) overload during reperfusion: using modeling to illuminate the mechanisms underlying a therapeutic failure.
Roberts BN, Christini DJ. Roberts BN, et al. PLoS Comput Biol. 2011 Oct;7(10):e1002241. doi: 10.1371/journal.pcbi.1002241. Epub 2011 Oct 20. PLoS Comput Biol. 2011. PMID: 22028644 Free PMC article. - The protective effect of Papaverine and Alprostadil in rat testes after ischemia and reperfusion injury.
Karagoz MA, Doluoglu OG, Ünverdi H, Resorlu B, Sunay MM, Demirbas A, Karakan T, Aydin A. Karagoz MA, et al. Int Braz J Urol. 2018 May-Jun;44(3):617-622. doi: 10.1590/S1677-5538.IBJU.2017.0600. Int Braz J Urol. 2018. PMID: 29617080 Free PMC article. - Targeting HIF-1_α_ to Prevent Renal Ischemia-Reperfusion Injury: Does It Work?
Sethi K, Rao K, Bolton D, Patel O, Ischia J. Sethi K, et al. Int J Cell Biol. 2018 Nov 25;2018:9852791. doi: 10.1155/2018/9852791. eCollection 2018. Int J Cell Biol. 2018. PMID: 30595695 Free PMC article. Review. - Beyond Reperfusion: Acute Ventricular Unloading and Cardioprotection During Myocardial Infarction.
Curran J, Burkhoff D, Kloner RA. Curran J, et al. J Cardiovasc Transl Res. 2019 Apr;12(2):95-106. doi: 10.1007/s12265-019-9863-z. Epub 2019 Jan 22. J Cardiovasc Transl Res. 2019. PMID: 30671717 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous